Literature DB >> 11669158

Iron saturation of serum ferritin in patients with adult onset Still's disease.

J ten Kate1, J P Drenth, M F Kahn, C van Deursen.   

Abstract

OBJECTIVE: Patients with Still's disease show a prominent acute phase reaction. Our hypothesis is that under these circumstances the iron uptake of ferritin will not keep pace with its synthesis, and is therefore not a valid reflection of the iron status in these patients.
METHODS: Previously we developed a method to measure the iron content of ferritin; we investigated the usefulness of this method to establish the iron status of patients with anemia of inflammation.
RESULTS: In 9 patients with adult onset Still's disease (AOSD) we observed high ferritin concentrations and measured the iron saturation of ferritin. The mean value of saturation was 9.1%, while saturation in the healthy control group was 17.8%, a statistically significant difference (p < 0.005). Soluble transferrin receptor concentrations indicated a functional iron deficiency.
CONCLUSION: We conclude that the acute phase ferritin in patients with AOSD contains less iron in comparison to ferritin in healthy controls. We suggest that soluble transferrin receptor is the method of choice in estimating the iron status of patients with an acute phase reaction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11669158

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

1.  Decoupling ferritin synthesis from free cytosolic iron results in ferritin secretion.

Authors:  Ivana De Domenico; Michael B Vaughn; Prasad N Paradkar; Eric Lo; Diane M Ward; Jerry Kaplan
Journal:  Cell Metab       Date:  2011-01-05       Impact factor: 27.287

2.  Clinical features and prognosis of adult-onset Still's disease: 75 cases from China.

Authors:  Zhenzhen Liu; Xiaoju Lv; Guangmin Tang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 3.  The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis.

Authors:  Hiroshi Kawabata
Journal:  Int J Hematol       Date:  2017-11-13       Impact factor: 2.490

4.  Adult-Onset Still's Disease: A Case Report.

Authors:  Ong Ping Seung; Wahinuddin Sulaiman
Journal:  Oman Med J       Date:  2011-09

5.  Evaluation of Ferritin and Transferrin Ratio as a Prognostic Marker for Hepatocellular Carcinoma.

Authors:  Ishaan Vohra; Bashar Attar; Vatsala Katiyar; Pedro Palacios; Tejinder Randhawa; Muhammad Arslan Baig; Estefania Flores; Yuchen Wang; Hemant Mutneja; Sachit Sharma; Prashanth Lingamneni; Muhammad Zain Farooq; Naveen Bhaskaran; Seema Gandhi; Gijo Vettiankal; Melchor Demetria
Journal:  J Gastrointest Cancer       Date:  2021-03

6.  Fever with persistent flagellate erythema in a primigravida: a rare presentation of adult-onset Still's disease.

Authors:  Riti Bhatia; Nidhi Kaeley; Ravi Kant; Ankith Basi
Journal:  BMJ Case Rep       Date:  2019-07-12

7.  Clinical features and hyperferritinemia diagnostic cutoff points for AOSD based on ROC curve: a Chinese experience.

Authors:  Fan Lian; Yu Wang; Xiuyan Yang; Hanshi Xu; Liuqin Liang
Journal:  Rheumatol Int       Date:  2010-08-27       Impact factor: 2.631

8.  Ferritin in adult-onset still's disease: just a useful innocent bystander?

Authors:  Bella Mehta; Petros Efthimiou
Journal:  Int J Inflam       Date:  2012-03-25

9.  Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still's disease: use in the differential diagnosis of hyperferritinemia.

Authors:  Yohei Kirino; Mitsuhiro Takeno; Mika Iwasaki; Atsuhisa Ueda; Shigeru Ohno; Akira Shirai; Heiwa Kanamori; Katsuaki Tanaka; Yoshiaki Ishigatsubo
Journal:  Arthritis Res Ther       Date:  2005-03-21       Impact factor: 5.156

Review 10.  COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy.

Authors:  Carlo Perricone; Elena Bartoloni; Roberto Bursi; Giacomo Cafaro; Giacomo Maria Guidelli; Yehuda Shoenfeld; Roberto Gerli
Journal:  Immunol Res       Date:  2020-08       Impact factor: 2.829

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.